Sunho Biologics Inc

02898

Company Profile

  • Business description

    Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.

  • Contact

    No. 198 Peninsula Middle Road, Dipu Street
    Room 302, Building 3
    Anji County
    Zhejiang Province
    Huzhou
    CHN

    http://www.sunho-bio.com.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    128

Stocks News & Analysis

stocks

Strong finish to the year for overvalued ASX share

A great fiscal 2025 but investors are ahead of themselves.
stocks

Our three most overvalued ASX shares

These three companies are trading at a significant premium to our fair value.
stocks

What does big US court decision mean for Google’s parent company Alphabet?

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,080.7039.80-0.44%
CAC 407,763.4728.630.37%
DAX 4023,718.8488.29-0.37%
Dow JONES (US)45,514.95114.090.25%
FTSE 1009,241.6220.180.22%
HKSE25,938.13304.221.19%
NASDAQ21,798.7098.310.45%
Nikkei 22543,459.29184.52-0.42%
NZX 50 Index13,253.7327.41-0.21%
S&P 5006,495.1513.650.21%
S&P/ASX 2008,803.5037.40-0.42%
SSE Composite Index3,807.2919.55-0.51%

Market Movers